Amytrapper Catheter: A Prototype Extracorporeal Device That Traps Blood Amyloid-β in a Rat Model of Alzheimer's
Rishi Raj Chhipa1, Biji T Kurien2,3, Robert H Scofield2,3,4
1Recombinant Technologies LLC, Cheshire, CT, USA.
Abstract:
Alzheimer's disease (AD) presents a pressing global health challenge, with amyloid-β (Aβ) accumulation in the brain being a hallmark feature. While monoclonal antibodies targeting Aβ have shown cognitive benefits, safety concerns remain. Here, we introduce the Amytrapper catheter, a novel extracorporeal device developed by Recombinant Technologies to trap circulating Aβ using a retro-inverso peptide conjugated to polyethylene glycol. Through in vivo experiments using a rat model of AD, we demonstrate significant reductions in blood Aβ levels and behavioral improvements following Amytrapper catheter treatment. This innovative approach holds promise as a disease-modifying therapy for AD, offering a complementary strategy to existing treatments and advocating for further clinical development.
More Related Videos
08:27Establishment of a Valuable Mimic of Alzheimer's Disease in Rat Animal Model by Intracerebroventricular Injection of Composited Amyloid Beta Protein
Published on: July 29, 2018
06:52Fabrication of Amyloid-β-Secreting Alginate Microbeads for Use in Modelling Alzheimer's Disease
Published on: July 6, 2019
